CN105593210B - 用于体内成像的咔唑化合物 - Google Patents

用于体内成像的咔唑化合物 Download PDF

Info

Publication number
CN105593210B
CN105593210B CN201480051648.XA CN201480051648A CN105593210B CN 105593210 B CN105593210 B CN 105593210B CN 201480051648 A CN201480051648 A CN 201480051648A CN 105593210 B CN105593210 B CN 105593210B
Authority
CN
China
Prior art keywords
compound
formula
tspo
vivo imaging
ppm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480051648.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105593210A (zh
Inventor
W.J.特里格
P.A.琼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Priority to CN201910451008.2A priority Critical patent/CN110229093B/zh
Publication of CN105593210A publication Critical patent/CN105593210A/zh
Application granted granted Critical
Publication of CN105593210B publication Critical patent/CN105593210B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480051648.XA 2013-09-20 2014-09-19 用于体内成像的咔唑化合物 Active CN105593210B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910451008.2A CN110229093B (zh) 2013-09-20 2014-09-19 用于体内成像的咔唑化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1316762.2A GB201316762D0 (en) 2013-09-20 2013-09-20 Novel compounds
GB1316762.2 2013-09-20
PCT/EP2014/069969 WO2015040148A1 (en) 2013-09-20 2014-09-19 Carbazole compounds for in vivo imaging

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910451008.2A Division CN110229093B (zh) 2013-09-20 2014-09-19 用于体内成像的咔唑化合物

Publications (2)

Publication Number Publication Date
CN105593210A CN105593210A (zh) 2016-05-18
CN105593210B true CN105593210B (zh) 2020-06-05

Family

ID=49553181

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480051648.XA Active CN105593210B (zh) 2013-09-20 2014-09-19 用于体内成像的咔唑化合物
CN201910451008.2A Active CN110229093B (zh) 2013-09-20 2014-09-19 用于体内成像的咔唑化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910451008.2A Active CN110229093B (zh) 2013-09-20 2014-09-19 用于体内成像的咔唑化合物

Country Status (6)

Country Link
US (1) US9951011B2 (enExample)
EP (1) EP3046904B1 (enExample)
JP (1) JP6401791B2 (enExample)
CN (2) CN105593210B (enExample)
GB (1) GB201316762D0 (enExample)
WO (1) WO2015040148A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110229093A (zh) * 2013-09-20 2019-09-13 通用电气健康护理有限公司 用于体内成像的咔唑化合物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109776394B (zh) * 2019-03-05 2020-10-27 朱晓琴 一种咔唑衍生物及其制备方法与制备h2s供体的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448933A (zh) * 2009-03-27 2012-05-09 通用电气健康护理有限公司 作为pbr配体的吲哚衍生物
CN103179991A (zh) * 2010-09-30 2013-06-26 通用电气健康护理有限公司 癌症的体内成像方法
CN103209713A (zh) * 2010-09-24 2013-07-17 通用电气健康护理有限公司 心境障碍的体内成像方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201316762D0 (en) * 2013-09-20 2013-11-06 Ge Healthcare Ltd Novel compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448933A (zh) * 2009-03-27 2012-05-09 通用电气健康护理有限公司 作为pbr配体的吲哚衍生物
CN103209713A (zh) * 2010-09-24 2013-07-17 通用电气健康护理有限公司 心境障碍的体内成像方法
CN103179991A (zh) * 2010-09-30 2013-06-26 通用电气健康护理有限公司 癌症的体内成像方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
[18F]GE-180: A novel fluorine-18 labelled PET tracer for imaging Translocator protein 18 kDa (TSPO);Harry Wadsworth et al;《Bioorganic & Medicinal Chemistry Letters》;20111227;第22卷;1308-1313 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110229093A (zh) * 2013-09-20 2019-09-13 通用电气健康护理有限公司 用于体内成像的咔唑化合物
CN110229093B (zh) * 2013-09-20 2022-12-13 通用电气健康护理有限公司 用于体内成像的咔唑化合物

Also Published As

Publication number Publication date
CN110229093B (zh) 2022-12-13
EP3046904A1 (en) 2016-07-27
EP3046904B1 (en) 2020-02-12
JP6401791B2 (ja) 2018-10-10
WO2015040148A1 (en) 2015-03-26
JP2016530337A (ja) 2016-09-29
CN110229093A (zh) 2019-09-13
GB201316762D0 (en) 2013-11-06
US20160214936A1 (en) 2016-07-28
CN105593210A (zh) 2016-05-18
US9951011B2 (en) 2018-04-24

Similar Documents

Publication Publication Date Title
CN102448933B (zh) 作为pbr配体的吲哚衍生物
CN103179991B (zh) 癌症的体内成像方法
JP5830519B2 (ja) Ｐｂｒリガンドとしての三環式インドール誘導体
US9168317B2 (en) In vivo imaging method of mood disorders
BRPI0808503B1 (pt) Composto, uso de um composto, e, composição farmacêutica
RU2512288C2 (ru) Производные индола, подходящие для визуализации нейровоспаления
CN105593210B (zh) 用于体内成像的咔唑化合物
JP2016534145A (ja) Ｐｂｒリガンドとしての四環式インドール誘導体のｓ−エナンチオマー
US9186424B2 (en) Aryloxyanilide imaging agents
WO2015040087A1 (en) Macrophage imaging
HK1167393B (en) Tricyclic indole derivates as pbr ligands

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant